ReviewFrontiers in immunology2018
Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Not just another shot: Tailoring vaccination in the era of modern liver transplantation.World journal of transplantation · 2026Review
- How Immunocompromised Hosts Were Left Behind in the Quest to Control the COVID-19 Pandemic.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Vaccine-Preventable Illness Leads to Adverse Outcomes in Liver Transplant Recipients.Digestive diseases and sciences · 2024Article
- Delayed acyclovir therapy for disseminated varicella zoster in an adult kidney transplant recipient: a case report and literature review.Annals of medicine and surgery (2012) · 2023Article
- Risk of Severe Alphaherpesvirus Infection after Solid Organ Transplantation: A Nationwide Population-Based Cohort Study.Biomedicines · 2023Article
- A Review of Cutaneous Diseases Observed in Solid Organ Transplant Recipients.The Journal of clinical and aesthetic dermatology · 2022Review
- COVID-19 Infection and Response to Vaccination in Chronic Kidney Disease and Renal Transplantation: A Brief Presentation.Life (Basel, Switzerland) · 2022Review
- Lesson of the month: Late, disseminated herpes zoster reactivation in a stem cell transplant recipient: implications for post-transplant prophylaxis and immune monitoring.Clinical medicine (London, England) · 2021Article
- Ageing of Immune System and Response to a Live-Attenuated Herpes Zoster Vaccine in Lung Transplant Candidates.Vaccines · 2021Article
- Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients.BMC infectious diseases · 2021Article
- Acute retinal necrosis following recombinant subunit varicella-zoster virus vaccine.American journal of ophthalmology case reports · 2020Article
- Shingles (Herpes Zoster) Mimicking Acute Abdomen.Cureus · 2020Article
- The situation of vaccines for the prevention of infections in adults: An opinion paper on the situation in Spain.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019Article
- Herpes Zoster in Kidney Transplant Recipients: A Series of Three Cases.Case reports in nephrology and dialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This narrative review focuses on the herpes zoster (HZ) and its prevention in transplant patients. Varicella zoster virus (VZV) is highly contagious and distributed worldwide in humans. Primary VZV infection usually causes varicella and then establishes a lifelong latency in dorsal root ganglia. Reactivation of VZV leads to HZ and related complications such as postherpetic neuralgia. Age and decreased immunity against VZV are important risk factors for developing HZ. Transplant patients are at increased risk for developing HZ and related complications due to their immunocompromised status and the need for lifetime immunosuppression. Diagnosis of HZ in transplant patients is often clinically difficult, and VZV-specific antibodies should be determined by serologic testing to document prior exposure to VZV during their pre-transplant evaluation process. Although antiviral agents are available, vaccination should be recommended for preventing HZ in transplant patients considering their complicated condition and weak organ function. Currently, there are two licensed HZ vaccines, of which one is a live-attenuated vaccine and the other is a HZ subunit vaccine. Both vaccines have shown promising safety and efficacy in transplants patients and especially the subunit vaccine could be administered post-transplant since this vaccine does not contain any live virus. Larger studies are needed about safety and immunogenicity of HZ vaccines in transplant populations, and extra efforts are needed to increase vaccine usage according to guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.